FR05C0040I1 - - Google Patents

Info

Publication number
FR05C0040I1
FR05C0040I1 FR05C0040C FR05C0040I1 FR 05C0040 I1 FR05C0040 I1 FR 05C0040I1 FR 05C0040 C FR05C0040 C FR 05C0040C FR 05C0040 I1 FR05C0040 I1 FR 05C0040I1
Authority
FR
France
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
Other languages
French (fr)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26799377&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR05C0040(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of FR05C0040I1 publication Critical patent/FR05C0040I1/fr
Application granted granted Critical
Publication of FR05C0040I2 publication Critical patent/FR05C0040I2/fr
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Dental Preparations (AREA)
  • Pyrane Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
FR05C0040C 1993-09-21 2005-09-21 Composes d'azetidinone hydroxy-substitues efficaces en tant qu'agents hypocholesterolemiques Active FR05C0040I2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10244093A 1993-09-21 1993-09-21
US08/257,593 US5631365A (en) 1993-09-21 1994-06-09 Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
PCT/US1994/010099 WO1995008532A1 (en) 1993-09-21 1994-09-14 Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents

Publications (2)

Publication Number Publication Date
FR05C0040I1 true FR05C0040I1 (pt) 2005-10-28
FR05C0040I2 FR05C0040I2 (fr) 2006-12-29

Family

ID=26799377

Family Applications (1)

Application Number Title Priority Date Filing Date
FR05C0040C Active FR05C0040I2 (fr) 1993-09-21 2005-09-21 Composes d'azetidinone hydroxy-substitues efficaces en tant qu'agents hypocholesterolemiques

Country Status (35)

Country Link
US (5) US5631365A (pt)
EP (1) EP0720599B1 (pt)
JP (1) JP2803908B2 (pt)
KR (1) KR100186853B1 (pt)
CN (1) CN1050830C (pt)
AT (1) ATE180249T1 (pt)
AU (1) AU681445C (pt)
BE (1) BE2014C056I2 (pt)
BR (1) BR1100159A (pt)
CA (1) CA2172149C (pt)
CZ (2) CZ288861B6 (pt)
DE (3) DE122004000026I2 (pt)
DK (1) DK0720599T3 (pt)
ES (1) ES2132432T3 (pt)
FI (1) FI110321B (pt)
FR (1) FR05C0040I2 (pt)
GE (1) GEP20043149B (pt)
GR (1) GR3030312T3 (pt)
HU (1) HU221185B1 (pt)
IL (1) IL110956A (pt)
LU (4) LU91050I2 (pt)
MA (1) MA23332A1 (pt)
MY (1) MY111314A (pt)
NL (2) NL300132I2 (pt)
NO (6) NO305902B1 (pt)
NZ (1) NZ274041A (pt)
PL (1) PL182617B1 (pt)
RU (1) RU2138480C1 (pt)
SG (1) SG46208A1 (pt)
SK (1) SK281067B6 (pt)
TN (1) TNSN94094A1 (pt)
TW (1) TW427974B (pt)
UA (1) UA41948C2 (pt)
WO (1) WO1995008532A1 (pt)
ZA (1) ZA947086B (pt)

Families Citing this family (244)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5688785A (en) * 1991-07-23 1997-11-18 Schering Corporation Substituted azetidinone compounds useful as hypocholesterolemic agents
US5631365A (en) * 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
MX9606319A (es) * 1994-06-20 1997-05-31 Schering Corp Compuestos de acetidinonas sustituidas utiles como agentes hipocolesterolemicos.
US6268392B1 (en) 1994-09-13 2001-07-31 G. D. Searle & Co. Combination therapy employing ileal bile acid transport inhibiting benzothiepines and HMG Co-A reductase inhibitors
US6642268B2 (en) 1994-09-13 2003-11-04 G.D. Searle & Co. Combination therapy employing ileal bile acid transport inhibiting benzothipines and HMG Co-A reductase inhibitors
US6262277B1 (en) * 1994-09-13 2001-07-17 G.D. Searle And Company Intermediates and processes for the preparation of benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
US5624920A (en) * 1994-11-18 1997-04-29 Schering Corporation Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents
US5633246A (en) * 1994-11-18 1997-05-27 Schering Corporation Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents
US5656624A (en) * 1994-12-21 1997-08-12 Schering Corporation 4-[(heterocycloalkyl or heteroaromatic)-substituted phenyl]-2-azetidinones useful as hypolipidemic agents
CA2231808C (en) * 1995-09-27 2007-05-22 Schering Corporation Stereoselective microbial reduction process
EP0766962A3 (en) * 1995-10-03 2000-05-10 Beiersdorf-Lilly GmbH Treatment of atherosclerosis
US5843938A (en) * 1995-10-03 1998-12-01 Beiersdorf-Lilly Gmbh Treatment of atherosclerosis
PT877750E (pt) * 1995-10-31 2002-09-30 Schering Corp 2-azetidinonas substituidas por acucar uteis como agentes hipocolesterolemiantes
WO1997016424A1 (en) * 1995-11-02 1997-05-09 Schering Corporation Process for preparing 1-(4-fluorophenyl)-3(r)-(3(s)-hydroxy-3-([phenyl or 4-fluorophenyl])-propyl)-4(s)-(4-hydroxyphenyl)-2-azetidinone
DE69734321T2 (de) 1996-02-23 2006-08-10 Eli Lilly And Co., Indianapolis Non-peptidische vasopressin via antagonisten
US5886171A (en) * 1996-05-31 1999-03-23 Schering Corporation 3-hydroxy gamma-lactone based enantioselective synthesis of azetidinones
US5739321A (en) * 1996-05-31 1998-04-14 Schering Corporation 3-hydroxy γ-lactone based enantionselective synthesis of azetidinones
US5756470A (en) * 1996-10-29 1998-05-26 Schering Corporation Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents
FR2762336B1 (fr) * 1997-04-21 1999-06-11 Francois Trantoul Procede de fabrication d'un film a motif non reproductible par lecture optique pour la protection de documents
US6133001A (en) * 1998-02-23 2000-10-17 Schering Corporation Stereoselective microbial reduction for the preparation of 1-(4-fluorophenyl)-3(R)-[3(S)-Hydroxy-3-(4-fluorophenyl)propyl)]-4(S)-(4 -hydroxyphenyl)-2-azetidinone
US5919672A (en) * 1998-10-02 1999-07-06 Schering Corporation Resolution of trans-2-(alkoxycarbonylethyl)-lactams useful in the synthesis of 1-(4-fluoro-phenyl)-3(R)- (S)-hydroxy-3-(4-fluorophenyl)-propyl!-4(S)-(4-hydroxyphenyl)-2-azetidinone
PT1137634E (pt) * 1998-12-07 2005-10-31 Schering Corp Processo para a sintese de azetidinonas
US6207822B1 (en) 1998-12-07 2001-03-27 Schering Corporation Process for the synthesis of azetidinones
CN1342089A (zh) 1998-12-23 2002-03-27 G.D.瑟尔有限公司 适用于心血管疾病的回肠胆汁酸转运抑制剂和胆固醇酯转移蛋白抑制剂的组合
EP1340509A1 (en) 1998-12-23 2003-09-03 G.D. Searle LLC. Combinations of cholesteryl ester transfer protein inhibitors and fibric acid derivatives for cardiovascular indications
WO2000038722A1 (en) 1998-12-23 2000-07-06 G.D. Searle & Co. COMBINATIONS OF CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITORS AND HMG CoA REDUCTASE INHIBITORS FOR CARDIOVASCULAR INDICATIONS
BR9916484A (pt) * 1998-12-23 2002-01-22 Searle Llc Combinações de inibidores do transporte de ácido biliar ileal e de agentes sequestrantes de ácido biliar em indicações cardiovasculares
WO2000038723A1 (en) 1998-12-23 2000-07-06 G.D. Searle Llc Combinations of cholesteryl ester transfer protein inhibitors and bile acid sequestering agents for cardiovascular indications
EP1140187B1 (en) * 1998-12-23 2003-09-03 G.D. Searle LLC. Combinations of an ibat inhibitor and a mtp inhibitor for cardiovascular indications
DE69908643T2 (de) * 1998-12-23 2004-05-13 G.D. Searle Llc, Chicago Kombinationen von cholesteryl ester transfer protein inhibitoren und nicotinsäure derivaten für kardiovaskuläre indikationen
EA200100707A1 (ru) 1998-12-23 2001-12-24 Джи.Ди.Сирл Ллс Сочетания ингибиторов транспорта желчных кислот в подвздошной кишке и производных фибриновой кислоты для сердечно-сосудистых показаний
EP2281899A3 (en) 1999-04-05 2012-01-04 Schering Corporation Stereoselective microbial reduction for the preparation of 1-(4-fluorophenyl)-3(R)-3(S)-hydroxy-3-(4-fluorophenyl)propyl)-4(S)-(4-hydroxyphenyl)-2-azetidinone
US6297268B1 (en) 1999-11-30 2001-10-02 Schering Corporation Imidazoles as cholesterol lowering agents
AU2001247331A1 (en) * 2000-03-10 2001-09-24 Pharmacia Corporation Combination therapy for the prophylaxis and treatment of hyperlipidemic conditions and disorders
US6794544B2 (en) 2000-03-10 2004-09-21 Pharmacia Corporation Method for the preparation of tetrahydrobenzothiepines
US6584357B1 (en) * 2000-10-17 2003-06-24 Sony Corporation Method and system for forming an acoustic signal from neural timing difference data
AU2002227240A1 (en) * 2000-10-30 2002-05-15 Schering Corporation Treatment and method using loratadine and montelukast
CA2432798C (en) 2000-12-20 2007-02-27 Schering Corporation Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents
EP1593670B1 (en) * 2000-12-20 2007-08-08 Schering Corporation Hydroxy-substituted 2-azetidinones useful as hypocholesterolemic agents
US6982251B2 (en) * 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
EP1510521A1 (en) * 2000-12-20 2005-03-02 Schering Corporation Sugar-substituted 2-Azetidinones useful as hypocholesterolemic agents
AU2002216097B2 (en) * 2000-12-21 2006-09-07 Sanofi-Aventis Deutschland Gmbh Novel 1,2-diphenzylazetidinones, method for producing the same, medicaments containing said compounds, and the use thereof for treating disorders of the lipid metabolism
IL156552A0 (en) 2000-12-21 2004-01-04 Aventis Pharma Gmbh Diphenyl azetidinone derivatives, method for the production thereof, medicaments containing these compounds, and their use
DE60216890T2 (de) * 2001-01-26 2007-08-30 Schering Corp. Kombinationen von einem hemmer der sterol-absorption und einem ppar-aktivator zur behandlung von kardiovaskulären indikationen
AR035739A1 (es) * 2001-01-26 2004-07-07 Schering Corp Composiciones farmaceuticas y combinaciones terapeuticas que comprenden secuestrante (s) de los acidos biliares y de inhibidor (es) de la absorcion de los esteroles y el uso de dichas composiciones para la manufactura de un medicamento para el tratamiento de indicaciones vasculares
AU2006202618B2 (en) * 2001-01-26 2007-04-19 Organon Llc Combinations of peroxisome proliferator-activated receptor (PPAR) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
AU2008201609B8 (en) * 2001-01-26 2009-01-08 Organon Llc Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitors(s) and treatments for vascular indications
AU2005246926B2 (en) * 2001-01-26 2008-02-28 Merck Sharp & Dohme Corp. The use of substituted azetidinone compounds for the treatment of sitosterolemia
AU2007201970B2 (en) * 2001-01-26 2008-04-17 Organon Llc Combinations of peroxisome proliferator-activated receptor (PPAR) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
CZ305202B6 (cs) * 2001-01-26 2015-06-10 Merck Sharp & Dohme Corp. Farmaceutický prostředek
RU2314126C2 (ru) * 2001-01-26 2008-01-10 Шеринг Корпорейшн Комбинации ингибитора (ингибиторов) всасывания стерина с модификатором (модификаторами) крови, предназначенные для лечения патологических состояний сосудов
EP1911462A3 (en) 2001-01-26 2011-11-30 Schering Corporation Compositions comprising a sterol absorption inhibitor
AU2006203175B2 (en) * 2001-01-26 2008-07-24 Organon Llc Combinations of peroxisome proliferator-activated receptor (PPAR) activators(s) and sterol absorption inhibitors(s) and treatments for vascular indications
US7071181B2 (en) * 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
AU2002240050A1 (en) * 2001-01-26 2002-08-06 Schering Corporation Combinations of nicotinic acid and derivatives thereof and sterol absorption inhibitor(s) and treatments for vascular indications
JP2004517919A (ja) * 2001-01-26 2004-06-17 シェーリング　コーポレイション 血管状態の処置のための心臓血管薬剤とステロール吸収インヒビターとの組み合わせ
TWI291957B (en) * 2001-02-23 2008-01-01 Kotobuki Pharmaceutical Co Ltd Beta-lactam compounds, process for repoducing the same and serum cholesterol-lowering agents containing the same
CA2442219C (en) 2001-03-28 2007-09-11 Schering Corporation Enantioselective synthesis of azetidinone intermediate compounds
PT1392287E (pt) * 2001-05-25 2007-02-28 Schering Corp Métodos para tratamento de doença de alzheimer e/ou regulação dos níveis de peptídeos β amilóide num sujeito
US20040077625A1 (en) * 2001-07-25 2004-04-22 Tremont Samuel J. Novel 1,4-benzothiazepine and 1,5-benzothiazepine compounds as inhibitors of apical sodium codependent bile acid transport abd taurocholate uptake
US20030119808A1 (en) * 2001-09-21 2003-06-26 Schering Corporation Methods of treating or preventing cardiovascular conditions while preventing or minimizing muscular degeneration side effects
SI1429756T1 (sl) * 2001-09-21 2007-02-28 Schering Corp Zdravljenje ksantomov z azetidinonskimi derivati kot inhibitorji absorpcije sterola
US7056906B2 (en) 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
US7053080B2 (en) * 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
AU2002336609B2 (en) * 2001-09-21 2006-08-24 Merck Sharp & Dohme Corp. Treatment of xanthoma with azetidinone derivatives as sterol absorption inhibitors
JP2005518347A (ja) * 2001-11-02 2005-06-23 ジー．ディー． サール エルエルシー 頂端ナトリウム共依存性胆汁酸輸送（ａｓｂｔ）およびタウロコール酸塩取り込みの阻害剤としての新規一および二フッ化ベンゾチエピン化合物
EP1451138A4 (en) * 2001-11-09 2005-06-15 Atherogenics Inc METHOD FOR REVERTING AND PREVENTING THE PROCESS OF CARDIOVASCULAR DISEASES
WO2003053359A2 (en) 2001-12-19 2003-07-03 Atherogenics, Inc. 1,3-bis-(substituted-phenyl)-2-propyn-1-ones and their use to treat disorders
WO2003053368A2 (en) * 2001-12-19 2003-07-03 Atherogenics, Inc. Chalcone derivatives and their use to treat diseases
FR2833842B1 (fr) * 2001-12-21 2004-02-13 Aventis Pharma Sa Compositions pharmaceutiques a base de derives d'azetidine
CA2471639A1 (en) 2002-01-17 2003-07-31 Pharmacia Corporation Novel alkyl/aryl hydroxy or keto thiepines.
EP1480689A1 (en) * 2002-02-28 2004-12-01 Eli Lilly And Company Method of treating atherosclerosis and hypercholesterolemia
US20040116510A1 (en) * 2002-03-05 2004-06-17 Nichtberger Steven A. Antihypertensive agent and cholesterol absorption inhibitor combination therapy
US20030204096A1 (en) * 2002-03-25 2003-10-30 Schering Corporation Enantioselective synthesis of azetidinone intermediate compounds
DE10227508A1 (de) * 2002-06-19 2004-01-08 Aventis Pharma Deutschland Gmbh Säuregruppen-substituierte Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
GB0215579D0 (en) * 2002-07-05 2002-08-14 Astrazeneca Ab Chemical compounds
JP4579681B2 (ja) 2002-07-09 2010-11-10 ブリストル−マイヤーズ スクイブ カンパニー 抗糖尿病薬および抗肥満薬として有用な置換ヘテロシクロ誘導体および方法
US20040132058A1 (en) 2002-07-19 2004-07-08 Schering Corporation NPC1L1 (NPC3) and methods of use thereof
US7135556B2 (en) * 2002-07-19 2006-11-14 Schering Corporation NPC1L1 (NPC3) and methods of use thereof
AR040588A1 (es) 2002-07-26 2005-04-13 Schering Corp Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa
ATE485818T1 (de) * 2002-07-30 2010-11-15 Karykion Inc Zusammensetzungen aus ezetimib und verfahren zur behandlung von mit cholesterin zusammenhängenden gutartigen und bösartigen tumoren
WO2004056727A2 (en) * 2002-12-19 2004-07-08 Atherogenics, Inc. Process of making chalcone derivatives
US7235543B2 (en) * 2003-03-07 2007-06-26 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
CN1756755A (zh) * 2003-03-07 2006-04-05 先灵公司 取代的2－吖丁啶酮化合物、其制剂及其治疗高胆甾醇血症的用途
JP4589919B2 (ja) * 2003-03-07 2010-12-01 シェーリング コーポレイション 高コレステロール血症の処置のための、置換アゼチジノン化合物、これらの処方物および使用
WO2004099132A2 (en) * 2003-05-05 2004-11-18 Ranbaxy Laboratories Limited Process for the preparation of trans-isomers of diphenylazetidinone derivatives
AR041089A1 (es) 2003-05-15 2005-05-04 Merck & Co Inc Procedimiento y composiciones farmaceutiicas para tratar aterosclerosis, dislipidemias y afecciones relacionadas
JP4901474B2 (ja) * 2003-05-30 2012-03-21 ランバクシー ラボラトリーズ リミテッド 置換ピロール誘導体
EP1635813A4 (en) * 2003-06-06 2009-07-01 Merck & Co Inc COMBINATION THERAPY FOR THE TREATMENT OF DYSLIPIDEMIA
CN1829519A (zh) * 2003-07-24 2006-09-06 默克公司 二苯基取代的环烷烃类,含有它们的组合物和应用的方法
AU2003259547A1 (en) * 2003-07-31 2005-02-14 Hetero Drugs Limited Ezetimibe polymorphs
EP1522541A1 (en) * 2003-10-07 2005-04-13 Lipideon Biotechnology AG Novel hypocholesterolemic compounds
WO2005042692A2 (en) * 2003-10-31 2005-05-12 Forbes Medi-Tech Inc. A method of inhibiting the expression of genes which mediate cellular cholesterol influx in animal cells and inhibiting the production of proteins resulting from the expression of such genes using cholesterol absorption inhibitors
US20050096307A1 (en) * 2003-11-05 2005-05-05 Schering Corporation Combinations of lipid modulating agents and substituted azetidinones and treatments for vascular conditions
EP1918000A2 (en) 2003-11-05 2008-05-07 Schering Corporation Combinations of lipid modulating agents and substituted azetidinones and treatments for vascular conditions
PT1682499E (pt) * 2003-11-10 2007-11-05 Microbia Inc 4-biarilil-1-fenilazetidin-2-onas
EP1687287A1 (en) * 2003-11-24 2006-08-09 Hetero Drugs Limited A novel process for ezetimibe intermediate
AU2004303742B2 (en) * 2003-12-23 2008-06-19 Astrazeneca Ab Diphenylazetidinone derivatives possessing cholesterol absorption inhibitory activity
AU2004308332B2 (en) * 2003-12-23 2008-04-10 Merck Sharp & Dohme Corp. Anti-hypercholesterolemic compounds
GB0329778D0 (en) * 2003-12-23 2004-01-28 Astrazeneca Ab Chemical compounds
EP1723414A4 (en) * 2004-01-16 2008-03-26 Merck & Co Inc NPC1L1 (NPC3) AND METHOD FOR IDENTIFYING ITS LIGANDS
CA2558766A1 (en) 2004-03-05 2005-09-22 The Trustees Of The University Of Pennsylvania The use of mtp inhibitors for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side effects
US20060211752A1 (en) 2004-03-16 2006-09-21 Kohn Leonard D Use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune/inflammatory diseases associated with toll-like receptor overexpression
US20050244367A1 (en) * 2004-05-03 2005-11-03 Ilypsa, Inc. Phospholipase inhibitors localized in the gastrointestinal lumen
MXPA06013456A (es) * 2004-05-21 2007-03-01 Sanofi Aventis Deutschland Metodo para producir derivados de 1,4-difenilazetidinona.
UA87854C2 (en) 2004-06-07 2009-08-25 Мерк Энд Ко., Инк. N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
WO2006004903A2 (en) * 2004-06-28 2006-01-12 Atherogenics, Inc. 1,2-bis-(substituted-phenyl)-2-propen-1-ones and pharmaceutical compositions thereof
WO2006026273A2 (en) * 2004-08-25 2006-03-09 Merck & Co., Inc. Method of treating atherosclerosis, dyslipidemias and related conditions
US20060046996A1 (en) 2004-08-31 2006-03-02 Kowa Co., Ltd. Method for treating hyperlipidemia
PE20060594A1 (es) * 2004-09-09 2006-08-18 Novartis Ag Composicion farmaceutica que contiene un agonista de ppar
WO2006039334A1 (en) * 2004-09-29 2006-04-13 Schering Corporation Combinations of substituted azetidonones and cb1 antagonists
ES2435790T3 (es) 2004-12-03 2013-12-23 Intervet International B.V. Piperazinas sustituidas como antagonistas de CB1
WO2006065709A2 (en) * 2004-12-15 2006-06-22 Schering Corporation Functional assays for cholesterol absorption inhibitors
US20130082232A1 (en) 2011-09-30 2013-04-04 Unity Semiconductor Corporation Multi Layered Conductive Metal Oxide Structures And Methods For Facilitating Enhanced Performance Characteristics Of Two Terminal Memory Cells
WO2006107936A1 (en) * 2005-04-04 2006-10-12 Pontificia Universidad Catolica De Chile The use of ezetimibe in the prevention and treatment of cholesterol gallstones
TW200726746A (en) 2005-05-06 2007-07-16 Microbia Inc Processes for production of 4-biphenylylazetidin-2-ones
JP2008543744A (ja) * 2005-05-09 2008-12-04 マイクロビア インコーポレーテッド 有機金属ベンゼンホスホナートカップリング剤
AU2006244043A1 (en) * 2005-05-11 2006-11-16 Microbia, Inc. Processes for production of phenolic 4-biphenylylazetidin-2-ones
US7737155B2 (en) 2005-05-17 2010-06-15 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
AU2006249905A1 (en) * 2005-05-25 2006-11-30 Microbia, Inc. Processes for production of 4-(biphenylyl)azetidin-2-one phosphonic acids
WO2006138163A2 (en) * 2005-06-15 2006-12-28 Merck & Co., Inc. Anti-hypercholesterolemic compounds
CN101243072A (zh) * 2005-06-20 2008-08-13 先灵公司 用作组胺h3拮抗剂的哌啶衍生物
SA06270191B1 (ar) * 2005-06-22 2010-03-29 استرازينيكا ايه بي مشتقات من 2- أزيتيدينون جديدة باعتبارها مثبطات لامتصاص الكوليسترول لعلاج حالات فرط نسبة الدهون في الدم
EP1893570A4 (en) * 2005-06-22 2009-12-23 Reddy Manne Satynarayana IMPROVED PROCESS FOR THE PREPARATION OF EZETIMIBE
AR054482A1 (es) * 2005-06-22 2007-06-27 Astrazeneca Ab Derivados de azetidinona para el tratamiento de hiperlipidemias
EP1741427A1 (en) * 2005-07-06 2007-01-10 KRKA, D.D., Novo Mesto Pharmaceutical composition comprising simvastatin and ezetimibe
US20070049748A1 (en) * 2005-08-26 2007-03-01 Uppala Venkata Bhaskara R Preparation of ezetimibe
WO2007030721A2 (en) * 2005-09-08 2007-03-15 Teva Pharmaceutical Industries Ltd. Processes for the preparation of (3r,4s)-4-((4-benzyloxy)phenyl)-1-(4-fluorophenyl)-3-((s)-3-(4-fluorophenyl)-3-hydroxypropyl)-2-azetidinone, an intermediate for the synthesis of ezetimibe
TW200806623A (en) * 2005-10-05 2008-02-01 Merck & Co Inc Anti-hypercholesterolemic compounds
AU2006304836A1 (en) 2005-10-21 2007-04-26 Novartis Ag Combination of a renin-inhibitor and an anti-dyslipidemic agent and/or an antiobesity agent
KR101329112B1 (ko) * 2005-11-08 2013-11-14 랜박시 래보러터리스 리미티드 (3ｒ,5ｒ)-7-〔2-(4-플루오로페닐)-5-이소프로필-3-페닐-4-〔(4-히드록시 메틸 페닐 아미노)카르보닐〕-피롤-1-일〕-3,5-디히드록시 헵탄산 헤미 칼슘염의 제조 방법
HU0501164D0 (en) * 2005-12-20 2006-02-28 Richter Gedeon Vegyeszet New industrial process for the production of ezetimibe
JP2009521452A (ja) * 2005-12-21 2009-06-04 シェーリング コーポレイション コレステロール降下剤およびｈ３受容体アンタゴニスト／逆アゴニストを使用する非アルコール性脂肪性肝疾患の処置
US20090227786A1 (en) * 2005-12-22 2009-09-10 Ana Gavalda I Escude Processes for preparing intermediate compounds useful for the preparation of ezetimibe
EP1973877A2 (en) 2006-01-18 2008-10-01 Schering Corporation Cannibinoid receptor modulators
WO2007094480A1 (ja) * 2006-02-16 2007-08-23 Kotobuki Pharmaceutical Co., Ltd. 光学活性アルコールを製造する方法
WO2007100807A2 (en) 2006-02-24 2007-09-07 Schering Corporation Npc1l1 orthologues
EP1849459A1 (en) * 2006-03-06 2007-10-31 Teva Pharmaceutical Industries Ltd. Ezetimibe compositions
US20070238716A1 (en) * 2006-03-14 2007-10-11 Murthy Ayanampudi S R Statin stabilizing dosage formulations
EP2004639A2 (en) * 2006-04-10 2008-12-24 Teva Pharmaceutical Industries Ltd Processes for the synthesis of azetidinone
AR060623A1 (es) * 2006-04-27 2008-07-02 Astrazeneca Ab Compuestos derivados de 2-azetidinona y un metodo de preparacion
US20070275052A1 (en) * 2006-05-24 2007-11-29 Glenmark Pharmaceuticals Limited Pharmaceutical compositions containing sterol inhibitors
EP2049102A4 (en) * 2006-07-14 2010-12-22 Ranbaxy Lab Ltd POLYMORPHIC FORMS OF AN HMG COA REDUCTASE HEATHER AND USE
JP2009503119A (ja) * 2006-08-29 2009-01-29 テバ ファーマシューティカル インダストリーズ リミティド （３ｒ，４ｓ）−４−（４−ヒドロキシ保護−フェニル）−１−（４−フルオロフェニル）−３−［３−（４−フルオロフェニル）−３−オキソプロピル］アゼチジン−２−オンを精製する方法
CA2661404A1 (en) * 2006-09-05 2008-03-13 Schering Corporation Pharmaceutical combinations for lipid management and in the treatment of atherosclerosis and hepatic steatosis
JP2010503678A (ja) * 2006-09-15 2010-02-04 シェーリング コーポレイション アゼチジノン誘導体およびその使用方法
CN101583612A (zh) * 2006-09-15 2009-11-18 先灵公司 治疗脂质代谢障碍的氮杂环丁酮衍生物
MX2009002922A (es) 2006-09-15 2009-04-01 Schering Corp Derivados de azetidina y azetidona utiles en el tratamiento del dolor y de trastornos del metabolismo lipidico.
WO2008033431A1 (en) * 2006-09-15 2008-03-20 Schering Corporation Spirocyclic azetidinone derivatives for the treatment of disorders of lipid metabolism, pain, diabetes and other disorders
CA2663500A1 (en) * 2006-09-15 2008-03-20 Schering Corporation Spiro-condensed azetidine derivatives useful in treating pain, diabetes and disorders of lipid metabolism
US20080085315A1 (en) * 2006-10-10 2008-04-10 John Alfred Doney Amorphous ezetimibe and the production thereof
CN100564357C (zh) * 2006-10-20 2009-12-02 浙江天宇药业有限公司 一种氮杂环丁酮衍生物及其合成方法
AU2007342603A1 (en) * 2006-12-20 2008-07-17 Merck Sharp & Dohme Corp. Anti-hypercholesterolemic compounds
US20080161279A1 (en) * 2006-12-21 2008-07-03 Wisler Gerald L Methods of Treating Obesity
EP1939174A1 (en) * 2006-12-21 2008-07-02 LEK Pharmaceuticals D.D. Inclusion complex of ezetimibe and a cyclodextrin and processes in the preparation thereof
WO2008089984A2 (en) * 2007-01-24 2008-07-31 Krka Process for the preparation of ezetimibe and derivatives thereof
WO2008096372A2 (en) * 2007-02-06 2008-08-14 Ind-Swift Laboratories Limited Process for preparing highly pure ezetimibe using novel intermediates
WO2008104875A1 (en) * 2007-03-01 2008-09-04 Pfizer Products Inc. Oxazolidinones as cholesterol absorption inhibitors
PE20081877A1 (es) 2007-03-06 2008-12-27 Teijin Pharma Ltd Derivado de la 1,4-diarilacetidinona
EP2134169A2 (en) 2007-03-09 2009-12-23 Indigene Pharmaceuticals Inc. Combination of metformin r-(+) lipoate and antihyperlipidemic agents for the treatment of diabetic hyperglycemia and diabetic complications
WO2008123953A1 (en) * 2007-04-02 2008-10-16 Merck & Co., Inc. Anti-hypercholesterolemic compound
WO2008130616A2 (en) * 2007-04-19 2008-10-30 Schering Corporation Diaryl morpholines as cb1 modulators
US8048880B2 (en) * 2007-05-03 2011-11-01 Anthera Pharmaceuticals, Inc. Treatment of cardiovascular disease and dyslipidemia using secretory phospholipase A2 (SPLA2) inhibitors and SPLA2 inhibitor combination therapies
US20090047716A1 (en) * 2007-06-07 2009-02-19 Nurit Perlman Reduction processes for the preparation of ezetimibe
US20080318920A1 (en) * 2007-06-19 2008-12-25 Protia, Llc Deuterium-enriched ezetimibe
US20080319221A1 (en) * 2007-06-22 2008-12-25 Bernd Junker Esters of Pentahydroxyhexylcarbamoyl Alkanoic Acids
US20080319218A1 (en) * 2007-06-22 2008-12-25 Andreas Haubrich Processes for Making and Using Benzyl Pentahydroxyhexylcarbamoylundecanoate
BRPI0814806A2 (pt) * 2007-06-28 2015-02-03 Intervet Int Bv Pirazinas substituídas como antagonistas de cb1
CA2694264A1 (en) * 2007-06-28 2009-01-08 Intervet International B.V. Substituted piperazines as cb1 antagonists
WO2009016358A2 (en) * 2007-07-27 2009-02-05 Cipla Limited Pharmaceutical compositions and process for making them
WO2009024889A2 (en) 2007-08-21 2009-02-26 Ranbaxy Laboratories Limited Pharmaceutical composition comprising a hmg-coa reductase inhibitor and ezetimibe
WO2009032264A1 (en) * 2007-08-30 2009-03-12 Teva Pharmaceutical Industries Ltd. Processes for preparing intermediates of ezetimibe by microbial reduction
WO2009027785A2 (en) * 2007-08-30 2009-03-05 Pfizer Products Inc. 1, 3-oxazole derivatives as cetp inhibitors
DE102007054497B3 (de) * 2007-11-13 2009-07-23 Sanofi-Aventis Deutschland Gmbh Neue kristalline Diphenylazetidinonhydrate und Verfahren zu deren Herstellung
ES2639995T3 (es) 2007-12-10 2017-10-31 Ratiopharm Gmbh Formulación farmacéutica que comprende ezetimiba
CZ305066B6 (cs) * 2008-02-25 2015-04-22 Zentiva, K.S. Způsob výroby (3R,4S)-1-(4-fluorfenyl)-3-[(3S)-3-(4-fluorfenyl)-3-hydroxypropyl)]-4-(4-hydroxyfenyl)-2-azetidinonu
EP2128133A1 (en) 2008-05-26 2009-12-02 Lek Pharmaceuticals D.D. Ezetimibe process and composition
WO2009147009A2 (en) * 2008-06-06 2009-12-10 Nicox S.A. Compositions comprising atorvastatin 4-(nitrooxy) butyl ester and a hypolipidemic drug
US20090312302A1 (en) * 2008-06-17 2009-12-17 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating nonalcoholic fatty liver disease-associated disorders
CN102186972B (zh) 2008-08-29 2014-08-20 科德克希思公司 用于立体选择性生产(4s)-3-[(5s)-5-(4-氟苯基)-5-羟基戊酰基]-4-苯基-1，3-噁唑烷-2-酮的酮还原酶多肽
EP2355812B1 (en) 2008-11-14 2019-07-10 Bomi P. Framroze Lowering circulating oxidized low density lipoprotein-beta-2-glycoprotein 1 complex for treatment of atherosclerosclerosis
EP2204170A1 (en) 2008-12-01 2010-07-07 LEK Pharmaceuticals D.D. Pharmaceutical composition comprising ezetimibe and simvastatin
US20110243940A1 (en) 2008-12-16 2011-10-06 Schering Corporation Bicyclic pyranone derivatives and methods of use thereof
US20110245209A1 (en) 2008-12-16 2011-10-06 Schering Corporation Pyridopyrimidine derivatives and methods of use thereof
EP2216016A1 (en) 2009-02-06 2010-08-11 LEK Pharmaceuticals d.d. Process for the preparation of a pharmaceutical composition comprising ezetimibe
WO2010100255A1 (en) 2009-03-06 2010-09-10 Lipideon Biotechnology Ag Pharmaceutical hypocholesterolemic compositions
ES2382773T3 (es) 2009-03-13 2012-06-13 Sanovel Ilac Sanayi Ve Ticaret A.S. Composiciones de ezetimiba
EP2414326B1 (en) 2009-03-31 2017-12-20 Lupin Limited Intermediates in the preparation of 1,4-diphenyl azetidinone
CA2757722C (en) 2009-04-01 2018-05-22 Matrix Laboratories Ltd. Enzymatic process for the preparation of (s)-5-(4-fluoro-phenyl)-5-hydroxy- 1morpholin-4-yl-pentan-1-one, an intermediate of ezetimibe and further conversion to ezetimibe
WO2011002424A2 (en) 2009-07-02 2011-01-06 Bilgic Mahmut Solubility and stability enchancing pharmaceutical formulation
WO2011002422A2 (en) 2009-07-02 2011-01-06 Bilgic Mahmut Solubility enhancing pharmaceutical formulation
EP2448919A2 (en) 2009-07-02 2012-05-09 Mahmut Bilgic Solubility and stability enchancing pharmaceutical formulation
CN101993403B (zh) 2009-08-11 2012-07-11 浙江海正药业股份有限公司 氮杂环丁酮类化合物及医药应用
ES2575560T3 (es) 2009-08-19 2016-06-29 Codexis, Inc. Polipéptidos cetorreductasa para preparar fenilefrina
CN107266681A (zh) 2010-02-24 2017-10-20 瑞立普萨公司 用作胆汁酸螯合剂的胺聚合物
CN105017481B (zh) 2010-02-24 2018-10-02 瑞立普萨公司 用作胆汁酸螯合剂的交联聚乙烯胺、聚烯丙胺和乙烯亚胺
WO2011106545A1 (en) 2010-02-24 2011-09-01 Relypsa, Inc. Polyimidazoles for use as bile acid sequestrants
EP2368543A1 (en) 2010-03-25 2011-09-28 KRKA, tovarna zdravil, d.d., Novo mesto Method of preparing a granulated pharmaceutical composition comprising simvastatin and/or ezetimibe
CN105214076B (zh) 2010-04-23 2020-03-31 辛那杰瓦生物制药股份有限公司 溶酶体贮积病酶
US9040262B2 (en) 2010-05-04 2015-05-26 Codexis, Inc. Biocatalysts for ezetimibe synthesis
ES2372460B1 (es) 2010-07-09 2012-11-16 Moehs Ibérica S.L. Nuevo método para la preparación de ezetimiba.
MX2013002704A (es) 2010-09-09 2013-09-13 Synageva Biopharma Corp Uso de acido lipasa lisosomal para tratar la deficiencia de acido lipasa lisosomal en pacientes.
AU2011326871B2 (en) 2010-11-08 2015-02-12 Albireo Ab IBAT inhibitors for the treatment of liver diseases
PT2637646T (pt) 2010-11-08 2016-08-17 Albireo Ab Uma combinação farmacêutica que compreende um inibidor do ibat e um sequestrador de ácido biliar
WO2012076030A1 (en) 2010-12-10 2012-06-14 Pharmathen S.A. Process for the preparation of intermediate compounds useful in the preparation of ezetimibe
EP2675472A4 (en) 2011-02-15 2014-09-17 Synageva Biopharma Corp METHOD FOR THE TREATMENT OF LACK OF LYSOSOMAL SAURER LIPASE
US8455474B2 (en) 2011-03-04 2013-06-04 Mackay Memorial Hospital Method for treating tuberculosis
WO2012155932A1 (en) 2011-05-17 2012-11-22 Pharmathen S.A. Improved process for the preparation of ezetimibe
PL231215B1 (pl) 2011-06-15 2019-02-28 Inst Chemii Organicznej Polskiej Akademii Nauk Sposób wytwarzania podstawionych azetydynonów oraz związków pośrednich do ich syntezy
CN102675177A (zh) * 2011-06-28 2012-09-19 常州制药厂有限公司 一种降血脂药物及其关键中间体的制备方法
CN102952055A (zh) * 2011-08-16 2013-03-06 凯瑞斯德生化(苏州)有限公司 一种依泽替米贝和其中间体的制备方法
CN103204795B (zh) * 2012-01-11 2016-12-14 重庆华邦胜凯制药有限公司 一种手性氮杂环丁酮类化合物的制备方法
US9763885B2 (en) 2012-05-01 2017-09-19 Althera Laboratories Ltd. Oral tablet formulation consisting of fixed combination of rosuvastatin and ezetimibe for treatment of hyperlipidemia and cardiovascular diseases
CN103570574B (zh) 2012-07-20 2016-04-13 中国科学院上海有机化学研究所 一种依泽替米贝的合成方法及该方法中所用的中间体
CN103102297A (zh) * 2012-09-28 2013-05-15 北京赛林泰医药技术有限公司 一种新的依折麦布的合成方法
TW201427658A (zh) 2012-12-10 2014-07-16 Merck Sharp & Dohme 藉由投予升糖素受體拮抗劑及膽固醇吸收抑制劑治療糖尿病之方法
CN103864708A (zh) * 2012-12-12 2014-06-18 天津市医药集团技术发展有限公司 一种依折麦布中间体的制备方法
WO2015039675A1 (en) 2013-09-23 2015-03-26 Pharmathen S.A. Novel process for the preparation of ezetimibe intermediates
EP3065736B1 (en) 2013-11-04 2018-11-14 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions thereof, and methods of use
WO2015092448A1 (en) 2013-12-18 2015-06-25 Rudjer Boskovic Institute Beta-lactam cholesterol absorption inhibitors
CN103739537B (zh) * 2013-12-24 2015-05-20 连云港恒运医药科技有限公司 依折麦布的新合成方法
KR20150079373A (ko) 2013-12-30 2015-07-08 한미약품 주식회사 에제티미브 및 로수바스타틴을 포함하는 경구용 복합제제
CN103755616A (zh) * 2013-12-31 2014-04-30 北京万全德众医药生物技术有限公司 一种制备依泽替米贝异构体的方法
US10328082B2 (en) 2014-05-30 2019-06-25 Pfizer Inc. Methods of use and combinations
CN105294426B (zh) 2014-06-09 2019-05-14 浙江海正药业股份有限公司 氮杂环丁酮化合物制备方法及其中间体
CN104447474A (zh) * 2014-11-11 2015-03-25 武汉武药科技有限公司 一种依折麦布异构体的合成方法
CN104387308A (zh) * 2014-11-18 2015-03-04 武汉福星生物药业有限公司 一种控制EZ-zanOH杂质产生制备高纯度依折麦布的方法
CN104513187B (zh) * 2015-01-09 2017-05-31 安润医药科技（苏州）有限公司 依折麦布及其中间体的合成方法
JP2016145173A (ja) * 2015-02-09 2016-08-12 株式会社トクヤマ （３ｒ，４ｓ）‐１‐（４‐フルオロフェニル）‐［３（ｓ）‐ヒドロキシ‐３‐（４‐フルオロフェニル）プロピル］‐（４‐ヒドロキシフェニル）‐２‐アゼチジノンの製造方法
CN107530307A (zh) 2015-03-13 2018-01-02 艾斯柏伦治疗公司 包含etc1002和依泽替米贝的固定剂量组合和制剂以及治疗心血管疾病或降低心血管疾病风险的方法
MA41793A (fr) 2015-03-16 2018-01-23 Esperion Therapeutics Inc Associations de doses fixes comprenant du etc1002 et une ou plusieurs statines permettant de traiter ou de réduire un risque cardiovasculaire
CN105287513A (zh) * 2015-10-23 2016-02-03 浙江永宁药业股份有限公司 一种依折麦布药物组合物及其制备方法
CN107098841A (zh) * 2016-02-19 2017-08-29 常州方楠医药技术有限公司 一种依折麦布的制备方法及该方法中所用的中间体
CN109791797B (zh) 2016-12-05 2023-05-02 智慧芽信息科技(苏州)有限公司 在大数据库中根据化学结构相似性搜索和显示可用信息的系统、装置和方法
US20180338922A1 (en) 2017-05-26 2018-11-29 Esperion Therapeutics, Inc. Fixed dose formulations
EP3437636A1 (en) 2017-08-02 2019-02-06 Adamed sp. z o.o. Pharmaceutical composition comprising ezetimibe
AU2019209458A1 (en) 2018-01-16 2020-07-02 Q.E.D. Environmental Systems, Inc. Fluid level monitoring system and method incorporating pressure sensor system having inflatable/collapsible bag
CA3133002A1 (en) 2019-03-20 2020-09-24 Regeneron Pharmaceuticals, Inc. Treatment of increased lipid levels with sterol regulatory element binding protein cleavage-activating protein (scap) inhibitors
CN113727732B (zh) 2019-03-20 2023-08-08 雷杰纳荣制药公司 用固醇调节元件结合转录因子1(srebf1)抑制剂治疗脂质水平升高
WO2021019499A1 (en) 2019-07-31 2021-02-04 TECNIMEDE - Sociedade Técnico-medicinal, SA Solid oral multiple-unit immediate release compositions, methods and uses thereof
EP4188338A1 (en) 2020-07-27 2023-06-07 KRKA, d.d., Novo mesto Bilayer tablet comprising ezetimibe and atorvastatin
CA3222897A1 (en) * 2021-06-17 2022-12-22 Xufei LI Hybutimibe intermediate and preparation method therefor
WO2023275715A1 (en) 2021-06-30 2023-01-05 Pfizer Inc. Metabolites of selective androgen receptor modulators
WO2024151311A1 (en) 2023-01-09 2024-07-18 Esperion Therapeutics, Inc. Methods of treatment using bempedoic acid

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2046823A1 (de) 1970-09-23 1972-03-30 Farbwerke Hoechst AG vormals Meister Lucius & Brüning, 6000 Frankfurt Neue Azetidinone-(2) und Verfahren zu deren Herstellung
CA1063108A (en) 1973-12-28 1979-09-25 Fujisawa, Pharmaceutical Co. Azetidinone derivatives and process for preparation thereof
US4576753A (en) 1975-10-06 1986-03-18 Fujisawa Pharmaceutical Co., Ltd. Azetidinone compounds and processes for preparation thereof
US4144232A (en) 1976-12-23 1979-03-13 Eli Lilly And Company Substituted azetidin-2-one antibiotics
US4375475A (en) * 1979-08-17 1983-03-01 Merck & Co., Inc. Substituted pyranone inhibitors of cholesterol synthesis
US4500456A (en) 1981-03-09 1985-02-19 Eli Lilly And Company Preparation of 4-fluoroazetidinones using FClO3
IL65158A0 (en) 1981-03-09 1982-05-31 Lilly Co Eli Azetidinones
US4784734A (en) 1981-04-10 1988-11-15 Otsuka Kagaku Yakuhin Kabushiki Kaisha Azetidinone derivatives and process for the preparation of the same
US4443372A (en) 1982-06-23 1984-04-17 Chevron Research Company 1-Alkyl derivatives of 3-aryloxy-4-(2-carbalkoxy)-phenyl-azet-2-ones as plant growth regulators
GR81665B (pt) 1983-02-02 1984-12-12 Univ Notre Dame Du Lac
US4595532A (en) 1983-02-02 1986-06-17 University Of Notre Dame Du Lac N-(substituted-methyl)-azetidin-2-ones
US4675399A (en) 1983-03-28 1987-06-23 Notre Dame University Cyclization process for β-lactams
US4565654A (en) 1983-03-28 1986-01-21 University Of Notre Dame Du Lac N-Acyloxy monocyclic β-lactams
WO1985004876A1 (en) 1984-04-24 1985-11-07 Takeda Chemical Industries, Ltd. 2-azetidinone derivatives and process for their preparation
US4576749A (en) 1983-10-03 1986-03-18 E. R. Squibb & Sons, Inc. 3-Acylamino-1-carboxymethylaminocarbonyl-2-azetidinones
US5229510A (en) 1983-12-01 1993-07-20 Merck & Co., Inc. β-lactams useful in determining the amount of elastase in a clinical sample
US4680391A (en) 1983-12-01 1987-07-14 Merck & Co., Inc. Substituted azetidinones as anti-inflammatory and antidegenerative agents
US5229381A (en) 1983-12-01 1993-07-20 Merck & Co., Inc. Substituted azetidinones as anti-inflammatory and antidegenerative agents
WO1985003707A1 (en) 1984-02-15 1985-08-29 Schering Corporation 8-CHLORO-6,11-DIHYDRO-11-(4-PIPERIDYLIDENE)-5H-BENZO AD5,6 BDCYCLOHEPTA AD1,2-b BDPYRIDINE AND ITS SALTS, PROCESSES FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS
US4581170A (en) 1984-08-03 1986-04-08 E. R. Squibb & Sons, Inc. N-hydroxyl protecting groups and process and intermediates for the preparation of 3-acylamino-1-hydroxy-2-azetidinones
US4633017A (en) 1984-08-03 1986-12-30 E. R. Squibb & Sons, Inc. N-hydroxy protecting groups and process for the preparation of 3-acylamino-1-hydroxy-2-azetidinones
CA1268780A (en) 1984-08-03 1990-05-08 Richard H. Mueller N-hydroxyl protecting groups and process for the preparation of 3-acylamino-1-hydroxy-2-azetidinones
US4620867A (en) 1984-09-28 1986-11-04 Chevron Research Company 1-carbalkoxyalkyl-3-aryloxy-4-(substituted-2'-carboxyphenyl)-azet-2-ones as plant growth regulators and herbicides
AU6849687A (en) 1986-01-23 1987-08-14 Upjohn Company, The Antimicrobial n-acyl-2-azetidinones
US4847271A (en) 1986-01-27 1989-07-11 Merck & Co., Inc. Antihypercholesterolemic β-lactones
USRE36481E (en) 1986-06-23 2000-01-04 Merck & Co., Inc. HMG-CoA reductase inhibitors
US4803266A (en) * 1986-10-17 1989-02-07 Taisho Pharmaceutical Co., Ltd. 3-Oxoalkylidene-2-azetidinone derivatives
US4816477A (en) 1987-05-26 1989-03-28 Merck & Co., Inc. Antihypercholesterolemic β-lactones
US4806564A (en) 1987-05-26 1989-02-21 Merck & Co., Inc. Antihypercholesterolemic beta-lactones
US4759923A (en) 1987-06-25 1988-07-26 Hercules Incorporated Process for lowering serum cholesterol using poly(diallylmethylamine) derivatives
US4834846A (en) 1987-12-07 1989-05-30 Merck & Co., Inc. Process for deblocking N-substituted β-lactams
EP0333268A1 (en) 1988-03-18 1989-09-20 Merck & Co. Inc. Process for synthesis of a chiral 3-beta hydrogen (3R) 4-aroyloxy azetidinone
NZ228600A (en) * 1988-04-11 1992-02-25 Merck & Co Inc 1-(benzylaminocarbonyl)-4-phenoxy-azetidin-2-one derivatives
JPH0645656B2 (ja) 1988-06-16 1994-06-15 出光石油化学株式会社 スチレン系共重合体およびその製造方法
US4952689A (en) 1988-10-20 1990-08-28 Taisho Pharmaceutical Co., Ltd. 3-(substituted propylidene)-2-azetidinone derivates for blood platelet aggregation
US4876365A (en) 1988-12-05 1989-10-24 Schering Corporation Intermediate compounds for preparing penems and carbapenems
FR2640621B1 (fr) 1988-12-19 1992-10-30 Centre Nat Rech Scient N-aryl-azetidinones, leur procede de preparation et leur utilisation comme inhibiteurs des elastases
CA2016467A1 (en) 1989-06-05 1990-12-05 Martin Eisman Method for treating peripheral atherosclerotic disease employing an hmg coa reductase inhibitor and/or a squalene synthetase inhibitor
JPH03108490A (ja) * 1989-06-30 1991-05-08 Shionogi & Co Ltd フォスフォリパーゼａ↓２阻害物質
US4983597A (en) 1989-08-31 1991-01-08 Merck & Co., Inc. Beta-lactams as anticholesterolemic agents
US5120729A (en) 1990-06-20 1992-06-09 Merck & Co., Inc. Beta-lactams as antihypercholesterolemics
IL99658A0 (en) 1990-10-15 1992-08-18 Merck & Co Inc Substituted azetidinones and pharmaceutical compositions containing them
EP0508425A1 (en) 1991-04-12 1992-10-14 Schering Corporation Bicyclic amides as inhibitors of acyl-coenzyme a: cholesterol acyl transferase
US5124337A (en) 1991-05-20 1992-06-23 Schering Corporation N-acyl-tetrahydroisoquinolines as inhibitors of acyl-coenzyme a:cholesterol acyl transferase
GB2264707A (en) 1991-06-18 1993-09-08 Roger Michael Marchbanks Acridine derivatives for treating alzheimer's disease
US5348953A (en) 1991-06-25 1994-09-20 Merck & Co., Inc. Substituted azetidinones as anti-inflammatory and antidegenerative agents
WO1993000332A1 (en) 1991-06-25 1993-01-07 Merck & Co., Inc. Substituted azetidinones as anti-inflammatory and antidegenerative agents
US5688785A (en) 1991-07-23 1997-11-18 Schering Corporation Substituted azetidinone compounds useful as hypocholesterolemic agents
CA2114007C (en) 1991-07-23 2005-12-20 Duane A. Burnett Substituted beta-lactam compounds useful as hypocholesterolemic agents and processes for the preparation thereof
US5688787A (en) 1991-07-23 1997-11-18 Schering Corporation Substituted β-lactam compounds useful as hypochlesterolemic agents and processes for the preparation thereof
MY131273A (en) 1991-07-23 2007-07-31 Schering Corp Substituted beta-lactam compounds useful as hypocholesterolemic agents and processes for the preparation thereof
JP2620437B2 (ja) * 1991-09-27 1997-06-11 宇部興産株式会社 ω−ヒドロキシ−（ω−３）−ケトニトリルおよびω−ヒドロキシ脂肪酸の製法
US5238950A (en) 1991-12-17 1993-08-24 Schering Corporation Inhibitors of platelet-derived growth factor
US5321031A (en) 1992-09-23 1994-06-14 Schering Corporation 1,2-disubstituted ethyl amides as inhibitors of ACAT
US5631363A (en) 1992-11-13 1997-05-20 Tanabe Seiyaku Co., Ltd. Azetidinone compound and process for preparation thereof
LT3300B (en) 1992-12-23 1995-06-26 Schering Corp Combination of a cholesterol biosynhtesis inhibitor and a beta- lactam cholesterol absorbtion inhibitor
LT3595B (en) 1993-01-21 1995-12-27 Schering Corp Spirocycloalkyl-substituted azetidinones useful as hypocholesterolemic agents
AU3494093A (en) 1993-01-22 1994-08-15 Institut National De La Sante Et De La Recherche Medicale (Inserm) S-lipophilic aliphatic carbonyl {n-mercaptoacyl-(amino acid or peptide)} compounds as antihypertensive agents
JPH08507068A (ja) 1993-02-26 1996-07-30 シェリング・コーポレーション ２−ベンジル−多環式グアニン誘導体およびそれらの製造方法
US5412092A (en) 1993-04-23 1995-05-02 Bristol-Myers Squibb Company N-substituted 2-azetidinones
US5550229A (en) 1993-06-23 1996-08-27 Tanabe Seiyaku Co., Ltd. Alkylation process for preparing azetidinone compound and starting compound therefor
ATE205475T1 (de) 1993-07-09 2001-09-15 Schering Corp Verfahren zur herstellung von azetidinonen
US5631365A (en) 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
US5627176A (en) 1994-03-25 1997-05-06 Schering Corporation Substituted azetidinone compounds useful as hypocholesterolemic agents
GB9406074D0 (en) 1994-03-26 1994-05-18 Glaxo Spa Chemical process
US5576470A (en) 1994-08-29 1996-11-19 Henkel Corporation Polyol esters of ether carboxylic acids and fiber finishing methods
US5624920A (en) 1994-11-18 1997-04-29 Schering Corporation Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents
US5633246A (en) 1994-11-18 1997-05-27 Schering Corporation Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents
US5595997A (en) 1994-12-30 1997-01-21 Sepracor Inc. Methods and compositions for treating allergic rhinitis and other disorders using descarboethoxyloratadine
WO1997016424A1 (en) 1995-11-02 1997-05-09 Schering Corporation Process for preparing 1-(4-fluorophenyl)-3(r)-(3(s)-hydroxy-3-([phenyl or 4-fluorophenyl])-propyl)-4(s)-(4-hydroxyphenyl)-2-azetidinone
US5739321A (en) 1996-05-31 1998-04-14 Schering Corporation 3-hydroxy γ-lactone based enantionselective synthesis of azetidinones
EP0855396A1 (en) 1997-01-22 1998-07-29 ASTA Medica Aktiengesellschaft Thioctic acid metabolites and methods of use thereof
EP1056455A4 (en) 1998-02-20 2000-12-06 Avmax Inc EPIMORPHIN COMPOUND AND USE OF THE SAME
US6465490B1 (en) 1999-07-16 2002-10-15 Aventis Pharmaceuticals Inc. Sulfuric acid mono-[3({1-[2-(4-fluoro-phenyl)-ethyl]-piperidin-4-yl}-hydroxy-methyl)-2-methoxy-phenyl]ester
EP1225880A2 (en) 1999-11-04 2002-07-31 Andrx Corporation Use of a hmg-coa reductase inhibitor for treating amyloid beta precursor disorders
AU2001240985B2 (en) 2000-04-07 2005-08-04 Pfizer Products Inc. Estrogen agonist/antagonist metabolites
US6982251B2 (en) 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents

Also Published As

Publication number Publication date
LU91050I2 (fr) 2004-10-12
NL300132I1 (nl) 2003-10-01
NL300132I2 (nl) 2003-11-03
GR3030312T3 (en) 1999-09-30
FI961300A0 (fi) 1996-03-21
FI110321B (fi) 2002-12-31
HUT73852A (en) 1996-09-30
DE122004000026I1 (de) 2004-11-18
JPH08509989A (ja) 1996-10-22
SK35596A3 (en) 1997-02-05
US5631365A (en) 1997-05-20
US5846966A (en) 1998-12-08
FR05C0040I2 (fr) 2006-12-29
HU9600697D0 (en) 1996-05-28
TW427974B (en) 2001-04-01
ES2132432T3 (es) 1999-08-16
KR100186853B1 (ko) 1999-05-01
PL182617B1 (pl) 2002-02-28
NL300172I1 (nl) 2005-04-01
DE10399001I2 (de) 2012-05-16
NL300172I2 (nl) 2005-08-01
LU92545I2 (fr) 2015-09-21
AU681445B2 (en) 1997-08-28
CN1050830C (zh) 2000-03-29
NO2014022I1 (no) 2014-09-10
SK281067B6 (sk) 2000-11-07
EP0720599B1 (en) 1999-05-19
AU681445C (en) 2004-07-08
MA23332A1 (fr) 1995-04-01
CN1131416A (zh) 1996-09-18
DE69418613T2 (de) 1999-09-30
SG46208A1 (en) 1998-02-20
MY111314A (en) 1999-10-30
EP0720599A1 (en) 1996-07-10
NO305902B1 (no) 1999-08-16
CA2172149C (en) 2000-11-28
DE10399001I1 (de) 2003-06-12
USRE42461E1 (en) 2011-06-14
IL110956A0 (en) 1994-11-28
FI961300A (fi) 1996-03-21
LU92544I2 (fr) 2015-01-20
NO961133L (no) 1996-03-20
JP2803908B2 (ja) 1998-09-24
GEP20043149B (en) 2004-01-12
DE69418613D1 (de) 1999-06-24
NO961133D0 (no) 1996-03-20
DE122004000026I2 (de) 2005-09-29
KR960704842A (ko) 1996-10-09
UA41948C2 (uk) 2001-10-15
NZ274041A (en) 1997-12-19
US5767115A (en) 1998-06-16
NO2017042I1 (no) 2017-08-02
HU221185B1 (en) 2002-08-28
ZA947086B (en) 1995-03-14
CZ83996A3 (en) 1996-08-14
ATE180249T1 (de) 1999-06-15
NO2003007I2 (no) 2005-08-29
USRE37721E1 (en) 2002-05-28
NO2005003I2 (no) 2005-10-03
NO2014023I1 (no) 2014-09-12
CZ288861B6 (cs) 2001-09-12
LU91160I2 (fr) 2005-11-25
AU7795294A (en) 1995-04-10
IL110956A (en) 2001-01-11
WO1995008532A1 (en) 1995-03-30
DK0720599T3 (da) 1999-11-08
PL313589A1 (en) 1996-07-08
TNSN94094A1 (fr) 1995-04-25
BE2014C056I2 (en) 2018-02-05
NO2005003I1 (no) 2005-02-28
RU2138480C1 (ru) 1999-09-27
BR1100159A (pt) 2006-09-26
CZ288891B6 (cs) 2001-09-12

Similar Documents

Publication Publication Date Title
FR2702022B1 (pt)
FR2707024B1 (pt)
FR2712517B1 (pt)
FR2706747B1 (pt)
EP0779577A3 (pt)
FR2707058B1 (pt)
FR2706801B1 (pt)
FR2706803B1 (pt)
EP0661322A3 (pt)
FR2706945B1 (pt)
FR2706827B1 (pt)
EP0641839A3 (pt)
FR2706894B1 (pt)
FR2706865B1 (pt)
FR2707067B1 (pt)
IN184422B (pt)
IN178572B (pt)
FR2716275B1 (pt)
FR2706940B1 (pt)
IN176909B (pt)
IN178007B (pt)
IN186444B (pt)
IN178647B (pt)
DK109393D0 (pt)
IN178546B (pt)